Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446704 | 1.00 | MAOA (0.41) | MAOASRCL3MBTL1MCL1KDM4E | |
| Ammonia Solution, Strong SCHEMBL629298 | 0.99 | L3MBTL1 (0.41) | MAOASRCL3MBTL1MCL1KDM4E | |
| SCHEMBL27739739 | 0.87 | KDM4E (0.42) | MAOASRCL3MBTL1MCL1KDM4E | |
| SCHEMBL14534729 | 0.84 | KDM4E (0.40) | L3MBTL1MCL1KDM4EALDH1A1LMNA | |
| SCHEMBL3489922 | 0.82 | KDM4E (0.41) | MAOAL3MBTL1MCL1KDM4EALDH1A1 | |
| SCHEMBL10265067 | 0.81 | MAOA (0.52) | MAOAL3MBTL1MCL1KDM4EALDH1A1 | |
| SCHEMBL27353376 | 0.81 | MAOA (0.42) | MAOAL3MBTL1MCL1KDM4EALDH1A1 | |
| Phosphoric Acid SCHEMBL1934555 | 0.79 | MCL1 (0.50) | MAOAL3MBTL1MCL1KDM4EALDH1A1 | |
| SCHEMBL2292509 | 0.78 | ALPL (0.44) | MAOAL3MBTL1MCL1KDM4EALDH1A1 | |
| SCHEMBL10205344 | 0.78 | KDM4E (0.46) | MAOAL3MBTL1MCL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637776-A1 | USE OF DUPD1 INHIBITORS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND METABOLIC DISORDERS | The Governing Council of the University of Toronto (CA) | 2025-10-29 | — | — | EP | claimed |
| US-12275782-B2 | Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells | MERZ PHARMA GMBH & CO. KGAA (DE) | 2025-04-15 | — | — | US | claimed |
| EP-4520824-A1 | DEOXYRIBOZYME THAT GENERATES FLUORESCENCE AND USES THEREOF | Ústav organické chemie a biochemie Akademie ved Ceske Republiky, v.v.i. (CZ) | 2025-03-12 | — | — | EP | claimed |
| US-20240270833-A1 | Means and Methods for the Determination of the Biological Activity of Neurotoxin Polypeptides in Cells | MERZ PHARMA GMBH & CO. KGAA (DE) | 2024-08-15 | — | — | US | claimed |
| WO-2024130444-A1 | USE OF DUPD1 INHIBITORS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND METABOLIC DISORDERS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2024-06-27 | — | — | WO | claimed |
| US-11976110-B2 | Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells | MERZ PHARMA GMBH & CO. KGAA (DE) | 2024-05-07 | — | — | US | claimed |
| US-10900955-B2 | Means and methods for the determination of the biological activity of BoNT/E in cells | MERZ PHARMA GMBH & CO. KGAA | 2021-01-26 | — | — | US | claimed |
| EP-3233911-B1 | MEANS AND METHODS FOR THE DETERMINATION OF THE BIOLOGICAL ACTIVITY OF BONT/E IN CELLS | MERZ PHARMA GMBH & CO KGAA (DE) | 2020-10-14 | — | — | EP | claimed |
| US-10605803-B2 | Composition for enzyme immunoassay using immunofluorescence and uses thereof | BIOMERIEUX (FR) | 2020-03-31 | — | — | US | claimed |
| US-20190023771-A1 | MEANS AND METHODS FOR THE DETERMINATION OF THE BIOLOGICAL ACTIVITY OF BONT/E IN CELLS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2019-01-24 | — | — | US | claimed |
| US-20030162213-A1 | Terminal-phosphate-labeled nucleotides and methods of use | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-08-28 | — | — | US | claimed |
| US-20030158083-A1 | Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase | THE PROCTER & GAMBLE COMPANY | 2003-08-21 | — | — | US | claimed |
| WO-2003056029-A2 | HIGHLY SENSITIVE AND CONTINUOUS PROTEIN-TYROSINE-PHOSPHATASE (PTPASE) TEST USING 6,8 DIFLUORO-4-METHYL-UMBELLIFERYLPHOSPHATE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-10 | — | — | WO | claimed |
| US-20030124576-A1 | Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-07-03 | — | — | US | claimed |
| US-20030096253-A1 | Single nucleotide amplification and detection by polymerase | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-05-22 | — | — | US | claimed |
| US-20030077610-A1 | Terminal-phosphate-labeled nucleotides and methods of use | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC | 2003-04-24 | — | — | US | claimed |
| WO-2003031930-A2 | A PHOSPHATASE ASSOCIATED WITH METASTASIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2003-04-17 | — | — | WO | claimed |
| WO-2003020984-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE | AMERSHAM BIOSCIENCES CORP (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003020734-A2 | LABELED NUCLEOSIDE POLYPHOSPHATES | AMERSHAM BIOSCIENCES CORP (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003020891-A2 | SINGLE NUCLEOTIDE AMPLIFICATION AND DETECTION BY POLYMERASE | AMERSHAM BIOSCIENCES CORP (US) | 2003-03-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124576-A1 | Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases | PNP, RNGTT, MTAP | MAOA 2036/4885SRC 3967/4885L3MBTL1 2211/4885 |
| US-20030077610-A1 | Terminal-phosphate-labeled nucleotides and methods of use | RNGTT, DNTT, PNP | MAOA 2612/4885SRC 3348/4885L3MBTL1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.